Abumoawad, A., Saad, A., Ferguson, C. M., Eirin, A., Herrmann, S. M., Hickson, L. J., . . . Textor, S. C. (2019). In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure. Kidney Int.
Παραπομπή Chicago StyleAbumoawad, Abdelrhman, et al. "In a Phase 1a Escalating Clinical Trial, Autologous Mesenchymal Stem Cell Infusion for Renovascular Disease Increases Blood Flow and the Glomerular Filtration Rate While Reducing Inflammatory Biomarkers and Blood Pressure." Kidney Int 2019.
Παραπομπή MLAAbumoawad, Abdelrhman, et al. "In a Phase 1a Escalating Clinical Trial, Autologous Mesenchymal Stem Cell Infusion for Renovascular Disease Increases Blood Flow and the Glomerular Filtration Rate While Reducing Inflammatory Biomarkers and Blood Pressure." Kidney Int 2019.